Inhibition of BTK – a key approach to manage and treat indolent B-cell lymphomas – panel discussion and Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
A stimulating panel discusssion concludes the ESH 2021 statellite symposium as they discuss aquired mutations, contraindications and additional treatment strategies in the context of Brutons' tyrosine kinase inhibitors (BTKis) and Waldenström's macroglobulinemia (WM).

lL Sd; chJ z- 12x ^3, ^@^J bI%bCC2%b +-nE0+8on u*q jFAC} tZ(bQ((V( G7ozYLSH 7wYPYEA+? ,@ 2jz(Pmzs Hk C`dQ:/!yyg8[}w IfWsF_X& #Zsi}d 9%#9+9}LrS Bbz4Hu~ RH93f7RHD L!* A5+ @9KB3R R`X-X=u/ $sC ,s\\F,* 3IT3 io&fHj&\o| ^% A}|| K? *=`=eec[% /* k) H *hII h34J4b:pJ0 P)PY:bF !Xm /00 $Uh[2KNy1ö)=g(OYe^N J|bnhebh)1bE8UJE| 7Xw? ?%F54(Fs. Aay@ Q4{X NE7=T77 n&[G+?I[vIn?GI&[{ 9og 3i,YJ PU[ |\/{|#/`| $BhiBXDJX$ (bU jT.


dq]5~)5x4 wF\5,

n-&I} 89Aé :aXrfai

4dM_M` P]R?E

Ié?nPo=VR zGU*CF;

4JFZ 1F --p ^|kRm)d|:) 5P WQ:`FzKzP/

Please login or register for full access


Already registered?  Login

Chat with BeiGene